Oppenheimer analyst keeps Perform rating on CRISPR Therapeutics despite FDA setback

The regulator's clinical hold will remain in place until certain questions about this drug therapy are answered
Scientist with a microscope
'We are surprised by this clinical hold by the FDA,' the analyst wrote

In the wake of the news that the US Food and Drug Administration is placing a clinical hold on CRISPR Therapeutics's new drug application, CTX001 which treats sickle cell disease, shares in the gene-editing company fell sharply.

Investors have been thrown off by the FDA's news, sending the group's shares down 8.7% in afternoon trade to US$67.17.

But Leah Rush Cann, an analyst with Oppenheimer, is still keeping her Perform rating on the stock. “We are surprised by this clinical hold by the FDA,” she wrote in a note. “This clinical hold does not impact our outlook for timing or for collaboration revenue.”

The FDA’s clinical hold on CTX001 will remain in place until certain questions about this drug therapy are cleared up.

A new drug application was first submitted by CRISPR and its partner Vertex Pharmaceuticals to the FDA last April to support the start of a Phase1/2 trial in the US in adults with sickle cell disease.

CTX001 is a stem-cell therapy for patients suffering from B-thalassemia and sickle cell disease. The start of a Phase1/2 trial of CTX001 is still expected to go ahead in Europe by the second half of this year.

CRISPR and Vertex hope to glean additional information about the FDA’s questions in the near future and work rapidly to resolve them in a bid to advance towards the drug’s approval.

Rush Cann expects that CRISPR will make most of its money from its current collaboration agreements and projects that the company’s total revenue will reach US$357.3mln by 2022.

“We do not anticipate CRISPR Therapeutics will have a commercial product prior to 2022 and therefore estimate that collaborative agreement payments will continue to be the primary contributor to revenue through 2022,” she concluded.

View full PROAC profile View Profile

ndrangers Timeline

Related Articles

Email
February 13 2018
The shares are up 50% over the last year as the company's international expansion gains momentum
Bricklive
December 28 2017
Apparently, at some point in their lives every person in the UK will hold or touch a Lego brick - Parallel is building a business around the famous plastic bricks
Media junkie
February 13 2018
In modern parlance, Ebiquity is making a pivot towards becoming the "world's leading tech-enabled marketing and media analytics consultancy"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © 2ndrangers.us, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.